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Abstract 
Purpose: To evaluate the anticancer activity of isoprenoids of Sarcophyton glaucum on MCF-7 cells 
and to investigate the potential synergistic effect of doxorubicin.  
Methods: Isolation and purification of isoprenoids were performed by applying different planar 
chromatographic methods (CC and PTLC). Further analyses of the isoprenoids by nuclear magnetic 
resonance (NMR) and mass spectrometry (MS) carried out to identify the compounds. Sulforhodamine-
B (SRB) assay was used to determine the cytotoxic activity of the compounds against the MCF-7 
human cell line. Flow cytometric analysis was used to assess their impact on cell cycle of MCF-7. 
Combination index (CI), when the compounds were combined with doxorubicin, was calculated to 
determine possible synergism. The isoprenoid compounds were also incubated at ¼ or ½ of their 
respective half-maximal concentration (IC50) with equimolar concentrations of doxorubicin. 
Results: Four known isoprenoid derivatives (1-4) were identified as 10(14)-aromadendrene (1), 
sarcophinediol (2), ent-deoxysarcophine (3) and sarcotrocheliol acetate (4). It was observed that cells 
accumulated in pre-G phase as well. CI of compound 3 with doxorubicin was 0.67 and 0.79, 
respectively, at ¼ and ½ of IC50, indicating overt synergism. This was confirmed by re-assessing the cell 
cycle stages of MCF-7 cells.  
Conclusion: The results indicate that compound 3 exhibits promising cytotoxicity as well as synergism 
with doxorubicin in MCF-7 cells. This is attributed, at least partly, to its ability to generate intercellular 
apoptosis induction. 
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The marine biota is characterized by ramification 
of the living organisms which live in the harsh 
perimeter [1]. Marine invertebrates, particularly 
soft corals, which lack of natural defenses (e.g., 
spines) lead to the production of defense 
metabolites [2].  
Alcyonacea or soft corals constitute important 
organisms of marine invertebrates which are 
ubiquitous in the tropical sea waters. Moreover, 
they are considered as a prolific source of unique 
antiproliferative metabolites [3-5]. For instance, 
eleutherobin, a tricyclic diterpene displayed high 
potency in the in vitro induction of tubulin 
polymerization. This marine natural factor 
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showed specific cytotoxicity toward several cell 
lines, including those of lung, ovarian, renal and 
lung [6]. The activity of eleutherobin in cancer 
cell therapy has been found to be comparable to 
that of taxol (a very active metabolite isolated 
from the terrestrial plant) [7].  
 
Cancer is a dreadful disease and is the direct 
cause of almost 14.5 % of all deaths across the 
world, which is found to increase with the aging 
of the population [8,9]. Amongst women, breast 
cancer is the most common type [10]. 
Anthracycline-based chemotherapy, particularly, 
doxorubicin (DOX) is used to treat early stage 
breast cancer [11]. However, it shows serious 
adverse effects, including cardiotoxicity [12]. 
Combining DOX with other cytotoxic agents has 
been suggested to enhance DOX cytotoxicity 
and avoid additional toxicity [8]. As combining 
factors with DOX, metabolites originated from 
natural sources (marine and terrestrial) and are 
strongly accepted from scientists and from the 
public communities, as well [13]. This recent 
paper further reported the cytotoxicity of 
isoprenoid derivatives (1-4) isolated from 
Sarcophyton glaucum (Figure 1) against MCF-7 
and the potential synergistic effect of combining 




Equipment and reagents 
 
Chromatography: TLC plates (GF 245 Si gel, 
Merck); PTLC plates (glass supported neutral 
Al2O3, 20 cm× 20 cm, 25 mm, Merck) and CC 
(60 G Si gel, Merck). Solvents and Reagents: 
CDCl3, TMS, 50 % H2SO4/CH3OH, were 
employed as a solvent for NMR measurements, 
an NMR internal standard, and a spray reagent, 
respectively. Doxorubicin, sulforhodamine-B 
(SRB) and dimethyl sulfoxide (DMSO) are 
Sigma-Aldrich products. Cell culture materials 
and fetal bovine serum are Lonza products. 
Instrument: NMR analysis (AVANCE III WM 600 
MHz (1H) and 150 MHz (13C), Bruker). TLC: Thin 
Layer Chromatography; PTLC: Prep. TLC; CC: 
Column Chromatography and TMS: 
Tetramethylsilane. 
 
Collection of S. glaucum 
 
In January 2014, at a depth of 5 - 10 m of North 
Jeddah Red Sea coast in Saudi Arabia, S. 
glaucum belonging to Alcyonacea (order; family 
Alcyoniidae) was collected by SCUBA divers. A 
voucher specimen (no. SC-2014-10) was kept at 
Faculty of Pharmacy, KAU, Jeddah, KSA. 
 
Extraction and isolation 
 
In a mixture of dichloromethane miscible with 
methanol (2:1), 5 kg of S. glaucum was extracted 
for 24 h (10 L × 3 batches, room temp.). The 
extract was then filtered, evaporated and 
extracted under vacuum to obtain a black sticky 
residue. Re-extraction of the organic residue 
between water and diethyl ether using a 
separating funnel followed by drying of the ether 
layer resulted in getting 30 g ether fraction 
soluble extract. 
 
The dried residue was physically partitioned on 
the Si gel column. The elution process was done 
using n-hexane, followed by a gradual increase 
in polarity with volumes of Et2O and then 
replaced volumes of EtOAc. 
 
 
Figure 1: Terpenoids from Sarcophyton glaucum 
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100 fractions were obtained (F 1-100), the 
homogeneity and the separation efficiency of the 
resulted fractions have been examined by 
investigating the TLC profile using 50 % sulfuric 
acid reagent or the UV lamp. Purification of 
fraction F-3 (300.0 mg) eluted with 5 % diethyl 
ether in n-hexane using prep. TLC with the same 
elution system (Violet-red zone with H2SO4 
reagent, Rf= 0.96, colorless oil, 22 mg, 1). 
Purification of another one, F-13 (125.0 mg) 
eluted with 25 % diethyl ether in n-hexane using 
prep. TLC with the same elution system afforded 
two distinguishable zones.  The zone with Rf = 
0.71 (violet color with H2 SO4 reagent, colorless 
oil, 16.0 mg, 3). The mixture n-hexane:EtOAC 
(9:1) eluted fraction F-41 (123.0 mg), which was 
subjected to purification applying prep. TLC 
using the same solvent system with a different 
ratio (8:2) to give a band at Rf = 0.71 (reddish 
color with H2 SO4 reagent, colorless oil, 12.0 mg, 
2). The last purified fraction, F-50 (70.0 mg), i.e., 
that eluted with a mixture of 25 % EtOAc in n-
hexane, was purified by HPLC with RP-18 
column and a composition of MeOH/H2O (65:35) 
to give metabolite 4 (3.0 mg). 
 
Cytotoxicity assays and viability analysis 
 
Sulforhodamine assay was performed as 
formerly described by Tolba et al [14]. By using 
0.25 % Trypsin-EDTA, exponentially growing 
cells were collected and coated in 96-well plates 
at 1000-2000 cells/well. The cells were laid bare 
for 48 hours to the compound under 
investigation, thereafter, in dark place incubation 
for 4 hours with SRB solution, which are then 
dissolved in DMSO. Measurement of color 
intensity was done at 750 nm. 
 
The equation % Cell viability = Emax× (1-M) + R is 
applied to estimate the dose response model of 
each metabolite, where R is the resistance 
fraction (unaffected portion) and M = [D]m/ [Kd]m + 
[D]m. 
 
Kd: compound concentration that causes a one-
half depress of the maximum inhibition rate, D: 
drug concentration used, and Emax =100-R. 
 
Analysis of cell cycle distribution 
 
The pre-estimated IC50 test compound was 
treated with cells for 24 hours. The cells were 
then collected by trypsinization, washed with ice-
cold phosphate buffer saline (PBS), and 
resuspended in PBS (0.5 ml). Smoothly added 
ice-cold EtOH (10 ml, 70 %) with vortexing then 
left the cells at 4 ºC for 1 h, the cells were kept at 
-20 ºC till analysis. At the time of analysis, 
specific cells were washed and re-suspended in 
1 ml of PBS containing 50 μg/ml RNase A and 
10 μg/ml propidium iodide (PI). FACSVantageTM 
was applied to analyze the DNA cells contents, 
after 20 min incubation at 37 ºC. 10,000 events 
were acquired for every sample. CELLQuest 
software was used to calculate the cell cycle 
distribution. Doxorubicin treated cells were 
employed as a positive control sample. 
 
Calculation of Combination Index 
 
Calculation of the Combination index (CI-value) 
was formerly described by Chou et al [15]. The 
growing cells exposed to equitoxic 
concentrations of didox and DOX were subjected 
to SRB assay, and Emax model used to calculate 
IC50. The CI= A/B + C/D equation determines the 
CI-value where A is the IC50 of compound X 
combination, B is the IC50 of compound X alone, 
C is the IC50 of drug compound combination and 
D are the IC50 of drug compound alone. 
 
Where: at CI= 0.8, the interaction of the drug 
works as synergism; when CI≥ 1.2, the 
interaction of the drug works as antagonism, 




The results are expressed as mean  SEM. 
Graph Pad InStat software, version 3.05 was 
used for statistical analysis. The data were 







Identification of the obtained isoprenoids was as 
follows: 
 
10(14)-Aromadendrene(1): 1H NMR (600 MHz): 
Chemical shift (δH)= 0.24 (1H, dd, 10.9, 9.3 Hz, 
H-6), 0.55 (1H, ddd, 10.9, 9.3, 5.9 Hz, H-7), 0.94 
(3H, d, 6.7 Hz, H-4), 0.96 (3H, s, H-12), 1.01 (3H, 
s, H-13). 4.74 (1H, s, Ha-14), 4.71 (1H, s, Hb-14); 
13C NMR (150 MHz) (δC)= C-1 to C-15: 50.8, 
28.3, 31.3, 37.9, 42.2, 23.6, 24.9, 22.2, 35.8, 
152.3, 17.2, 15.9, 28.7, 109.8, and 16.4, 
respectively. The aforementioned data coincide 
with those reported in 10(14)-aromadendrene 
[16]. 
 
Sarcophinediol (2): 1H NMR (600MHz):  
Chemical shift (δH)= 6.43 (1H, d, 10.8 Hz, H-1), 
5.96 (1H, dd, 10.8, 1.8 Hz, H-3), 2.02 (1H, m, H-
5),1.30 (1H, m H-5), 2.86 (1H, dd, 6.6, 4.8 Hz, H-
7), 5.12 (1H, dd, 6.6,12.6 Hz, H-11), 1.92 (2H, m, 
H-13), 3.66 (1H, d, 7.8 Hz, H-16), 3.46 (1H, d, 
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7.8 Hz, H-16), 1.33 (3H, s, H-17), 1.80 (3H, s, H-
18), 1.25 (3H, s, H-19),1.60 (3H, s, H-20); 13C 
NMR (150 MHz) (δC)= C-1 to C-20: 144.0, 120.0, 
121.0, 138.0, 38.5, 23.2, 62.3, 60.0, 25.9, 26.3, 
125.3, 135.7, 35.6, 41.2, 76.2, 68.9, 16.1, 17.8, 
24.3, and 17.0; respectively. The aforementioned 
data are coincide with those reported for 
Sarcophinediol [17]. 
 
Deoxosarcophine (3):1H NMR (600MHz):  
Chemical shift (δH)= 5.52 (1H, br d, 9.0 Hz, H-2), 
5.23 (1H, d, 9.0 Hz, H-3), 2.34 (2H, m, H-5), 2.7 
(1H, t, 7.2Hz, H-7), 2.10  5.10 (1H, dd, J = 6.0, 
4.8 Hz, H-11), 1.91 (2H, m, H-13), 2.54 (1H, m, 
H-14a), 1.66 (1H, m, H-14b), 4.49 (2H, m, H-16), 
1.65 (3H, s, H-17), 1.61 (3H, s, H-18), 1.27 (3H, 
s, H-19), 1.83 (3H, br s, H-20); 13C NMR (150 
MHz) (δC)= C-1 to C-20: 128.0, 83.7, 126.3, 
139.5, 38.0, 25.3, 62.0, 60.0, 39.9, 23.5, 123.6, 
136.8, 36.9, 26.1, 131.4, 78.3, 10.2, 15.1, 16.9, 
and 15.6; respectively. The aforementioned data 
coincide with those reported for deoxosarcophine 
[17]. 
 
Sarcotrocheliol acetate (4): 1H NMR (600MHz):  
Chemical shift (δH)=  1.26 (1H, m, H-1), 4.52 (1H, 
dd, 10.8, 5.4 Hz, H-2), 5.50 (1H, d, J = 10.8 Hz, 
H-3), 5.05 (1H, dd, 10.2, 4.8 Hz, H-7), 5.37 (1H, 
d, J = 10.2 Hz, H-11), 1.17 (1H, m, H-15), 0.69 
(3H, d, 6.6 Hz, H-16), 0.82 (3H, d, 6.6 Hz, H-17), 
1.62 (3H, s, H-18), 1.56 (3H, s, H-19), 1.04 (3H, 
s, H-20), 2.06 (s, CH3CO); 13C NMR (150 MHz): 
δC = 171.0 (C=O), 21.3 (CH3CO), 46.5, 71.4, 
125.3, 139.0, 39.8, 25.3, 124.5, 135.0, 34.4, 29.0 
, 73.5, 73.7, 34.3, 19.0, 29.0, 20.3,  20.7, 15.0, 
17.0, and 25.4; respectively. The aforementioned 
data coincide with those reported for 
sarcotrocheliol acetate [18]. 
 
Cytotoxicity assays and viability analysis 
 
The antiproliferative activity of factors 1-4 were 
evaluated against the MCF-7 cell line and the 
results showed IC50 values of 18.70 ±1.10, 8.80 ± 
0.90, 13.9 ± 1.00 and 18.5± 1.60 mg/ml, 
respectively.  
 
Cell cycle distribution 
 
The study of the possible mode action of the 
antiproliferative effects of 1, 2, 3, and 4, thus, the 
cell cycle analysis was evaluated (Figures 2 and 
3).All compounds decreased the population in S 
phase from 31.99 ± 2.90 to 18.39 ± 1.91, 16.10 ± 
1.71, 10.27 ± 0.81 and 22.63 ± 1.81 %.  
Moreover, they induced a compensatory 
increase in the population in the fraction G0/G1 
(non-proliferating cells) from 55.42 ± 1.30 to 
73.46 ± 2.81, 68.63 ± 1.80, 59.17 ± 1.31 and 
66.16 ± 0.151 %. All compounds induced 
compensatory decreased the population of MCF-
7 in G2/M phase from 10.82 ± 1.10 to 7.02 ± 
0.61, 13.50 ± 1.81, 5.28 ± 0.60 and 6.66 ± 1.30 
%, respectively. Finally, compound 3, increased 
the accumulation of MCF-7 population in the pre-




Table 1: Cytotoxicity of the combination, and combination Index of compounds 1-4 against MCF-7a 
 
Compound 
IC50  (μM) 
IC50 Combination IC50b CI
c Combination IC50d CI 
1 18.70 ±1.10 8.70 ±0.81e 08.16 5.00 ± 0.60 04.69 
2 08.80 ±0.90 13.50±0.90 13.48 9.70 ± 0.92 09.69 
3 13.90±1.00 0.70±0.07 00.67 0.81 ± 0.09 00.79 
4 18.50±1.60 11.00±1.04 09.78 12.90 ± 1.50 12.11 
Doxorubicin 1.13±0.08 -  -  
aMCF-7 (human breast Cancer cell line); b IC50 of the combination of ¼ IC50 of doxorubicin and ¼ IC50 of the 
compounds; cCombination Index was calculated according to Chou and Talalay equation; dIC50 of the 
combination of ½ IC50 of Doxorubicin and ½ IC50 of the compounds; edata are presented as Mean ± standard 
error of the mean (n = 3) 
 
Table 2: FACSCAN results of the marine samples in MCF-7 
 
Sample Cell cycle phase (%) 
Pre-G Go/G1 * S G2/M 
Control 1.77 ± 0.20 55.42 ± 1.30 31.99 ± 2.90 10.82 ± 1.10 
1 1.13 ± 0.091 73.46 ±2.81 18.39 ± 1.91 7.02 ± 0.61 
2 1.75 ± 0.035 68.63 ± 1.80 16.10 ± 1.71 13.50 ± 1.81 
3 23.28 ± 1.61 59.17 ± 1.31 10.27 ± 0.81 5.28 ± 0.60 
4 1.55 ± 0.051 66.16 ± 0.151 22.63 ± 1.81 6.66 ± 1.30 
Data are presented as mean + SEM (N = 3); * Significantly different from corresponding control value at p < 
0.05 
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Figure 2: FACSCAN of the tested compounds MCF-7 cancer cells were exposed to compounds (1-4). 
DNA cytometry analysis was used to determine cell cycle distribution and different cell phases were 
plotted as percent of total events (n = 3)  
 
 
Figure 3: Effect of combination of DOX and 3 on the MCF-7 cell cycle distribution. Cells were 
assayed with doxorubicin and combination of doxorubicin. DNA cytometry analysis was used to 
determine cell cycle distribution and different cell phases were plotted as percent of total events (n = 
3). 
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Compounds 1-4 exhibited cytotoxic activity 
against MCF-7 cells with IC50 ≤ 20 µM. These 
compounds have been estimated by the flow 
cytometry assay aimed at evaluating their effects 
on the cell cycle of MCF-7 cells. The CI 
(combination index) was evaluated to discover 
the possible synergistic potential, thus, 
decreasing the doxorubicin concentration and 
side effects. 
 
The capability of inducting of intercellular 
apoptosis could be the main reason of the 
observed antiproliferative activity of the tested 
compounds. Thus, the combination index (Table 
2) was used to calculate the synergistic potential. 
This was performed by incubating the reagents 
together with the equimolar concentration of 1/4 
and 1/2 of the IC50 concentration of both 
doxorubicin and compounds 1-4. The IC50 values 
of all combinations had increases than those 
obtained from either DOX alone or the 
compounds 1-4alone, except for compound 3, 
that showed decreases in the IC50to 
be0.70±0.07 and 0.81 ± 0.09 µM (Table 1). While 
the IC50of the combinations, DOX and 
compounds 1, 2, and 4 have been increased. 
Compounds 1, 2, and 4 showed synergistic 
activity when combined with the doxorubicin in 
the range 4.69 to 13.48, which indicate the 
antagonistic effects. Compound 3 showed 
synergistic activity when combined with the 
doxorubicin with combination indices (IC) values, 
0.67 and 0.79 which fully agree with the Chou 





Chemical investigation of Red Sea marine animal 
S. glaucum, led to the isolation of four 
compounds belonging to the mevalontes (1-4). 
All compounds showed cytotoxic activity with IC50 
in the range 8.80 ± 0.90 to 18.70 ± 1.10 µM 
against breast cancer cell lines (MCF-7). The 
antiproliferative activity of the test compounds 
can be ascribed to their ability to induce 
intercellular apoptosis. Compound 3 produced a 
synergistic effect with doxorubicin while the 
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